ArticleInternational journal of retina and vitreous2026
Short-term effects of oral curcumin as adjunct to intravitreal bevacizumab in diabetic macular edema: a randomized clinical trial.
Article in International journal of retina and vitreous, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the efficacy of combined oral curcumin and intravitreal bevacizumab (IVB) in diabetic macular edema (DME).
methodsThis clinical trial was conducted using a parallel-group, randomized, placebo-controlled design in patients with DME. All participants received IVB at the standard dose at monthly intervals for a total of three doses. Additionally, they were assigned to receive either oral curcumin capsules (40 mg) or a matched placebo every 12 h for three months, starting at the time of the first IVB injection. Treatment efficacy was assessed by comparing changes in foveal, perifoveal, and parafoveal retinal thickness, central macular volume (CMV), and LogMAR-corrected distance visual acuity (CDVA). Hemoglobin A1c (HbA1c) tests were performed for all patients at baseline and at three months.
resultsFifty-two eyes of 52 patients (26 eyes per group) completed the study. The patients' baseline characteristics were comparable between the groups. Macular thickness and CMV decreased significantly from baseline in both groups, with no statistically significant difference observed between the groups. Similarly, changes in LogMAR CDVA did not differ significantly between the intervention and control groups (MD: 0.08, [95% CI: -0.04 to 0.20]; P = 0.12). Both groups demonstrated a significant reduction in HbA1c levels at three months compared to baseline; however, the difference in HbA1c changes between the groups was statistically significant (P < 0.001), favoring the curcumin group (MD: 0.63%, 95% CI: [0.3-1.0]). No specific systemic or ocular adverse effects were observed in either group during the study.
conclusionAdjunctive treatment with oral curcumin in patients receiving IVB for DME was associated with a significantly greater reduction in HbA1c levels. Despite this metabolic outcome, oral curcumin did not provide additional detectable anatomical or functional benefit over intravitreal bevacizumab alone during the three-month follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.